BioCentury | Sep 12, 2019
Preclinical News

Sept. 12 Preclinical Quick Takes: Stephen Quake newco reveals epigenomic platform; plus Personal Genome, Summit and Biolife4D

...cleared bacterial burden in mouse models of sepsis, pneumonia and urinary tract infection comparable to tigecycline...
BioCentury | Aug 15, 2019
Distillery Therapeutics

Computationally designed antimicrobial peptide for drug-resistant infection

...disease INDICATION: Gram-negative bacterial infection A computationally designed 20-amino acid peptide could treat carbapenem- and tigecycline-resistant...
...tigecycline-resistant A. baumannii infection, compared with a rate of 12.5% for meropenem and 0% for tigecycline...
BioCentury | Jun 30, 2018
Regulation

Not a test

...with confirmed CRE infections. It compared Zemdri to colistin on a background of meropenem or tigecycline...
...therapy was permitted for up to 72 hours. In addition, adjunctive therapy with meropenem or tigecycline...
BioCentury | Oct 10, 2017
Distillery Therapeutics

Cancer

...Tygacil tigecycline decreased proliferation, colony formation, mitochondrial respiration and oxidative phosphorylation compared with vehicle, and Tygacil...
...and colony formation compared with either agent alone. In a xenograft mouse model of CML, Tygacil...
...BCR-ABL) inhibitor Gleevec for CML and several other hematologic malignancies and cancers. Pfizer Inc. markets Tygacil...
BioCentury | Dec 16, 2016
Clinical News

Plazomicin: Ph III CARE data

...of the open-label, international Phase III CARE trial showed that IV plazomicin plus meropenem or tigecycline...
...the primary endpoint, vs. 50% for colistin plus meropenem or tigecycline. Plazomicin plus meropenem or tigecycline...
...to a 28-day all-cause mortality rate of 11.8% vs. 40% for colistin plus meropenem or tigecycline...
BioCentury | Sep 5, 2016
Clinical News

Plazomicin: Completed Phase III enrollment

...CARE trial comparing IV plazomicin plus meropenem or tigecycline vs. IV colistin plus meropenem or tigecycline...
BioCentury | Sep 14, 2015
Politics, Policy & Law

IPR battles

...patents for rosacea drug Oracea doxycycline from Galderma S.A. , Pfizer Inc .'s antibiotic Tygacil tigecycline...
BioCentury | May 18, 2015
Politics, Policy & Law

Cut bait

...Date IPR filed Mcap change week of Mcap change to 5/15 Pfizer Inc. (NYSE:PFE) Tygacil tigecycline...
BioCentury | Sep 22, 2014
Clinical News

Plazomicin: Phase III started

...III trial comparing IV plazomicin plus meropenem or tigecycline vs. IV colistin plus meropenem or tigecycline...
...2006 (see BioCentury, Feb. 6, 2006). Pfizer Inc. (NYSE:PFE, New York, N.Y. ) markets Tygacil tigecycline...
BioCentury | Dec 17, 2013
Financial News

Stem Cell Therapeutics raises $31.2 million

...Therapeutics' pipeline includes two Phase I programs and two preclinical stem cell programs. The company's tigecycline...
Items per page:
1 - 10 of 65